| Dr Hans C Oettgen, MD, PHD | |
|
300 Longwood Ave, Boston, MA 02115-5724 | |
| (617) 355-6117 | |
| Not Available |
| Full Name | Dr Hans C Oettgen |
|---|---|
| Gender | Male |
| Speciality | Allergy/immunology |
| Experience | 37 Years |
| Location | 300 Longwood Ave, Boston, Massachusetts |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1245325174 | NPI | - | NPPES |
| 3122880 | Medicaid | MA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207K00000X | Allergy & Immunology | 72308 (Massachusetts) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Boston Children's Hospital | Boston, MA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Children's Hospital Pediatric Associates, Inc | 3476541830 | 246 |
News Archive
Vertex Pharmaceuticals Incorporated today announced the initiation of a Phase 3b study called CONCISE that will evaluate the potential for treatment with INCIVEK (telaprevir) combination therapy to be shortened to 12 weeks in people with genotype 1 chronic hepatitis C who have the 'CC' variation near the IL28B gene.
A group of Hokkaido University researchers has developed a paper-based device that can easily and cheaply measure lithium ion concentration in blood, which could greatly help bipolar disorder patients.
Tarsa Therapeutics, Inc. today announced completion of its global Phase III ORACAL trial testing the company's once-daily oral recombinant calcitonin for the treatment of postmenopausal osteoporosis. Results from the ORACAL trial are expected in early spring. In addition, Tarsa announced initiation of a new Phase II study of its oral calcitonin for the prevention of postmenopausal osteoporosis.
The investigational antiviral remdesivir is superior to the standard of care for the treatment of COVID-19, according to a report published today in The New England Journal of Medicine.
The U.S. Food and Drug Administration today cleared the first contact lens to incorporate an additive that automatically darkens the lens when exposed to bright light.
› Verified 2 days ago
| Entity Name | Children's Hospital Pediatric Associates, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1457306664 PECOS PAC ID: 3476541830 Enrollment ID: O20040504000964 |
News Archive
Vertex Pharmaceuticals Incorporated today announced the initiation of a Phase 3b study called CONCISE that will evaluate the potential for treatment with INCIVEK (telaprevir) combination therapy to be shortened to 12 weeks in people with genotype 1 chronic hepatitis C who have the 'CC' variation near the IL28B gene.
A group of Hokkaido University researchers has developed a paper-based device that can easily and cheaply measure lithium ion concentration in blood, which could greatly help bipolar disorder patients.
Tarsa Therapeutics, Inc. today announced completion of its global Phase III ORACAL trial testing the company's once-daily oral recombinant calcitonin for the treatment of postmenopausal osteoporosis. Results from the ORACAL trial are expected in early spring. In addition, Tarsa announced initiation of a new Phase II study of its oral calcitonin for the prevention of postmenopausal osteoporosis.
The investigational antiviral remdesivir is superior to the standard of care for the treatment of COVID-19, according to a report published today in The New England Journal of Medicine.
The U.S. Food and Drug Administration today cleared the first contact lens to incorporate an additive that automatically darkens the lens when exposed to bright light.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Hans C Oettgen, MD, PHD 300 Longwood Ave, Boston, MA 02115-5724 Ph: (617) 355-6117 | Dr Hans C Oettgen, MD, PHD 300 Longwood Ave, Boston, MA 02115-5724 Ph: (617) 355-6117 |
News Archive
Vertex Pharmaceuticals Incorporated today announced the initiation of a Phase 3b study called CONCISE that will evaluate the potential for treatment with INCIVEK (telaprevir) combination therapy to be shortened to 12 weeks in people with genotype 1 chronic hepatitis C who have the 'CC' variation near the IL28B gene.
A group of Hokkaido University researchers has developed a paper-based device that can easily and cheaply measure lithium ion concentration in blood, which could greatly help bipolar disorder patients.
Tarsa Therapeutics, Inc. today announced completion of its global Phase III ORACAL trial testing the company's once-daily oral recombinant calcitonin for the treatment of postmenopausal osteoporosis. Results from the ORACAL trial are expected in early spring. In addition, Tarsa announced initiation of a new Phase II study of its oral calcitonin for the prevention of postmenopausal osteoporosis.
The investigational antiviral remdesivir is superior to the standard of care for the treatment of COVID-19, according to a report published today in The New England Journal of Medicine.
The U.S. Food and Drug Administration today cleared the first contact lens to incorporate an additive that automatically darkens the lens when exposed to bright light.
› Verified 2 days ago
Dr. David H. Sachs, M.D. Allergy & Immunology Medicare: Not Enrolled in Medicare Practice Location: Bldg. 149-9019, 13th Street, Boston, MA 02466 Phone: 617-726-4065 Fax: 617-726-4067 | |
Dr. Anne Esther Goldfeld, M.D. Allergy & Immunology Medicare: Not Enrolled in Medicare Practice Location: 800 Huntington Ave, Boston, MA 02115 Phone: 617-278-3351 Fax: 617-278-3454 | |
Dr. Sachin Niranjan Baxi, M.D. Allergy & Immunology Medicare: Medicare Enrolled Practice Location: 300 Longwood Ave, Fegan 6, Boston, MA 02115 Phone: 617-919-2489 Fax: 617-730-0310 | |
Dr. Richard Arthur Moscicki, MD Allergy & Immunology Medicare: Not Enrolled in Medicare Practice Location: 15 Parkman St, Allergy Associates Wac 626, Boston, MA 02114 Phone: 617-726-3764 Fax: 617-252-7694 | |
Abduarahmn Almutairi, MD Allergy & Immunology Medicare: Not Enrolled in Medicare Practice Location: 300 Longwood Ave, Boston, MA 02115 Phone: 617-355-6117 | |
John L Ohman, MD Allergy & Immunology Medicare: Medicare Enrolled Practice Location: 750 Washington St, Nemc Box 30, Boston, MA 02111 Phone: 617-636-5000 Fax: 617-636-4843 | |
Dr. Paul J. Maglione, MD, PHD Allergy & Immunology Medicare: Accepting Medicare Assignments Practice Location: 725 Albany St, Shapiro 9 Suite B, Boston, MA 02118 Phone: 617-638-7480 |